Back to Search
Start Over
J&J trial miss may be viewed positively for CG Oncology, says BofA
- Source :
- The Fly. October 8, 2024
- Publication Year :
- 2024
-
Abstract
- After Johnson & Johnson (JNJ) announced that the company discontinued the SunRISe-2 trial, which evaluated TAR-200 + cetrelimab in muscle-invasive bladder cancer, or MIBC, patients due to the lack of [...]
Details
- Language :
- English
- Database :
- Gale General OneFile
- Journal :
- The Fly
- Publication Type :
- Periodical
- Accession number :
- edsgcl.811536131